A new approach to actinic keratosis in aging skin
Rubedo’s RLS-1496 1% cream is an experimental topical actinic keratosis treatment that targets age-related cellular damage to reduce precancerous skin lesions while aiming for better tolerability than current options. Actinic keratosis (AK) appears as rough, scaly patches on sun‑exposed areas like the face, scalp, hands and arms, and some lesions can progress to squamous cell carcinoma. In a Phase 1b/2a study, RLS-1496 was applied for four weeks to AK lesions, with untreated areas serving as controls. Rubedo reports that treated lesions fell by 46%, while control areas saw an 11% reduction over the same period. According to Rubedo CEO Frederick Beddingfield III, “A 46% reduction in AK lesions at four weeks, achieved with minimal irritation, is exciting since so many patients are hesitant to use current treatments due to redness, peeling, pain, and weeks-long recovery.”
Why tolerability matters in precancerous skin lesion care
AK affects an estimated tens of millions of older adults and is often viewed as a nuisance rather than a warning sign of cumulative sun damage. Yet some of these precancerous skin lesions advance to squamous cell carcinoma, so dermatologists encourage early treatment. Existing therapies can be effective but frequently cause redness, peeling, crusting, swelling and pain that may persist for weeks. This burden leads many patients to delay, interrupt or avoid treatment, creating a hidden compliance gap in actinic keratosis treatment. Rubedo’s early data point to an alternative: in the first 18 of 24 patients, RLS-1496 achieved lesion reduction with no serious adverse events, no discontinuations and only minimal local irritation reported. If these safety and comfort signals hold in larger trials, a more acceptable topical option could bring more people into care sooner, strengthening both cancer prevention and overall skin health.
From anti-aging skin cream to longevity dermatology tool
While RLS-1496 looks like another anti-aging skin cream on the surface, it reflects a deeper longevity dermatology strategy. Rubedo is developing compounds that act on senescent cells – damaged, aging cells that persist instead of dying and release inflammatory signals. These “bad neighbors” may worsen tissue function over time. RLS-1496 is designed as a GPX4 modulator that selectively targets dysfunctional cells while supporting recovery of stressed but still viable cells. Rubedo’s Chief Scientific Officer Marco Quarta describes the drug as part of a new class of “Adaptive SenoTherapeutics,” aimed at clearing damaged senescent cells and restoring healthier cellular function. Earlier Phase 1b work in plaque psoriasis, atopic dermatitis and photo‑aged skin adds weight to the idea that one mechanism could benefit multiple age‑related skin problems, pushing anti-aging research beyond cosmetics toward disease prevention.
Skin as a proving ground for longevity medicine
Skin provides a convenient testbed for longevity medicine because change is visible and measurable within weeks or months, not years. For companies like Rubedo, conditions such as actinic keratosis, psoriasis, atopic dermatitis and photo‑aged skin offer practical entry points: they are common, clinically important and tightly linked to aging biology. Success in AK does not guarantee success in organs like the liver, brain or muscle, but it can signal that targeting senescent cells and related pathways is worth exploring in fibrosis, metabolic disease, sarcopenia and neurodegeneration. The current RLS-1496 results come from a small, early-stage trial, and a larger Phase 2b study is planned. Many experimental therapies fail as they scale up, so caution is warranted. Still, a topical cream that reduces precancerous lesions while remaining gentle could mark an early, concrete win for longevity-driven dermatology.
